Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Huashi Baidu granule for mild or asymptomatic COVID-19
ChiCTR2200058668Phase 4Completed
- Sponsor
- Shuguang Hospital
- Start
- May 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4 trial of Huashi Baidu Granule in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by Shuguang Hospital. Primary endpoints: Nucleic acid negative conversion rate and Time to nucleic acid negative conversion. Started May 2022; status: completed.
02
Drugs
Huashi Baidu Granule
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on ChiCTR2200058668.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200058668.